	PTO/SB/05 (05-03) Approved for use through 04/30/2003. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE								
Under the Paperwork Reduction Act of 1995, no persons are requ	uired to respond to a collection of information unless it displays a valid OMB control number. **Aftorney Docket No. PZ033P1C2**								
UTILITY	First Inventor Steven M. Ruben								
PATENT APPLICATION	Steven W. Ruben								
TRANSMITTAL	Title 31 Human Secreted Proteins								
(Only for new nonprovisional applications under 37 CFR 1.53(b))	0								
	Express Mail Label No.								
APPLICATION ELEMENTS	MS Patent Application Commissioner for Patents ADDRESS TO: P.O. Roy 1450								
See MPEP chapter 600 concerning utility patent application con									
Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing) Applicant claims small entity status. See 37 CFR 1.27. X Specification [Total Pages 33! (preferred arrangement set forth below) - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. X Paper (92 pages) c. X Statements verifying identity of above copies								
 Background of the Invention Brief Summary of the Invention 	ACCOMPANYING APPLICATIONS PARTS								
 Brief Description of the Drawings (if filed) Detailed Description 	Assignment Papers (cover sheet & document(s))								
 Claim(s) Abstract of the Disclosure 	10. 37 CFR 3.73(b) Statement Power of (when there is an assignee) Attorney								
4. Drawing(s) (35 U.S.C. 113) [Total Sheets	11. English Translation Document (if applicable)								
	12 Information Disclosure Copies of IDS								
	Statement (IDS)/PTO-1449								
Converteem a prior application (37 CER 1 63(d))	Detum Descript and Carial Number Rectaurds (MDER 502)								
b. X (for continuation/divisional with Box 18 completed)	(Should be specifically itemized)								
i. DELETION OF INVENTOR(S) Signed statement attached deleting	15. Certified Copy of Priority Document(s) (if foreign priority is claimed) Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i).								
inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	Applicant must attach form PTO/SB/35 or its equivalent.								
	17. Other:								
6. X Application Data Sheet. See 37 CFR 1.76									
18. If a CONTINUING APPLICATION, check appropriate box, following the title, or in an Application Data Sheet under 37 CFF	and supply the requisite information below and in the first sentence of the specification								
1 7 1 1 1	n-in-part (CIP) of prior application No.: 09/820,893								
Prior application information: Examiner Alexand	der Spiegler Art Unit: 1637								
For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.									
19. CC	ORRESPONDENCE ADDRESS								
X Customer Number or Bar Code Label	or Correspondence address below 22195								
Name									
Address									
City Sta	ate Zip Code								
 	elephone Fax								
Name (Print/Type) Mark J. Hyman	Registration No. (Attorney/Agent) 46,789								
Signature AAAAAA	Date June 27, 2003								

			U.S. P	atent ar	nd Trademark	Office; U.S.	ugh 04/30/2003. OME DEPARTMENT OF C	OMMERCE	
Under the Paperwork Reduction Act of 1995, no persons are requ	espond t	pond to a collection of information unless it displays a valid OMB control number. Complete if Known							
FEE TRANSMITTAL						Not Yet Assigned			
						Concurrently Herewith			
for FY 2003	Filing Date				Steven M. Ruben				
Effective 01/01/2003, Patent fees are subject to annual revision.						Not Yet Assigned			
						N/A			
Applicant claims small entity status. See 37 CFR 1.27	Atom					PZ033P1C2			
TOTAL AMOUNT OF PAYMENT (\$) 906.00	Attorney Docket No.								
METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)						ntinued)		
Check Credit Money Other None	3. ADDITIONAL FEES								
X Deposit Account	Large Entity Small Entity								
Deposit Account 08-3425	Fee Fee Fee					Fee Description			
Number	Code	(\$)	Code	(\$)		. 00 2000		Fee Paid	
Deposit Account Human Genome Sciences, Inc.	1051	130	2051	65	Surcharge -	- late filing fee	e or oath		
Name The Director is hereby authorized to: (check all that apply)	1052	50	2052	25	Surcharge sheet.	rcharge - late provisional filing fee or cover eet.			
X Charge fee(s) indicated below X Credit any overpayments	1053	130	1053	130	Non-English specification				
X Charge any additional fee(s) during the pendency of this	1812	2,520	1812	2,520	For filing a re	equest for ex p	arte reexamination		
application		920*	1804	920*		publication o	f SIR prior to		
Charge fee(s) indicated below, except for the filing fee	1804			1,840*	Examiner as Requesting	ction publication o	f SIR after		
to the above-identified deposit account.	!	1,840*	1805	-	Examiner ad		first month		
FEE CALCULATION 1. BASIC FILING FEE	1251 1252	110 410	2251	55 205		or reply within or reply within	second month	 	
Large Entity Small Entity	1253	930	2253	465		or reply within			
Fee Fee Fee Fee <u>Fee Description</u> Fee Paid	1254	1,450	2254	725			fourth month		
Code (\$) Code (\$) 1001 750 2001 375 Utility filing fee 750.00	1255	1,970	2255	985	Extension for reply within fifth month			\vdash	
1002 330 2002 165 Design filing fee	1401	320	2401	160	Notice of Appeal				
1003 520 2003 260 Plant filing fee	1402	320	2402	160	Filing a brief in support of an appeal				
1004 750 2004 375 Reissue filing fee	1403	280	2403	140	Request for oral hearing				
1005 160 2005 80 Provisional filing fee	1451		1451			•	lic use proceeding	<u> </u>	
SUBTOTAL (1) (\$) 750.00	1452 1453		2452 2453	55 650		evive – unavo evive - uninte			
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501	1,300	2501	650		y issue fee (or reissue)			
Extra Fee from	1502		2502	235	Design issu		,		
Total Claims 24 -20** = 4 x 18.00 = 72.00	1503		2503	315	Plant issue	fee			
Independent 4 -3** = 1 x 84.00 = 84.00	1460	130	1460	130	Petitions to	ions to the Commissioner			
Claims Unitiple Dependent =	1807	50	1807	50	Processing	fee under 37	CFR 1.17(q)		
Large Entity Small Entity	1806	180	1806	180	Submission	of Information	n Disclosure Stmt		
Fee Fee Fee Fee Fee Description	8021	40	8021	40	Recording each patent assignment per				
Code (\$) Code (\$)	1809	750	2809	375	Filing a sub	property (times number of properties) Filing a submission after final rejection			
1201 84 2201 42 Independent claims in excess of 3					(37 ČFR 1.129(a)) For each additional invention to be			$\vdash \vdash \vdash$	
1203 280 2203 140 Multiple dependent claim, if not paid	1810		2810	375	examined (examined (37CFR 1.129(b))			
1204 84 2204 42 ** Reissue independent claims over original patent	1801	Populart for expedited examination					$\vdash\vdash\vdash$		
1205 18 2205 9 ** Reissue claims in excess of 20	1802	of a design application					·	\vdash	
and over original patent	Other fee (specify)							ليب	
SUBTOTAL (2) (\$) 156.00 **or number previously paid, if greater; For Reissues, see above **Or number previously paid, if greater; For Reissues, see above									
SUBMITTED BY Complete (if applicable)									
Name (Print/Type) Mark J. Hyman Registration No. (Attorney/Agent) 46,789							(240) 314-1224		
Signature MI W						Date	June 27, 2003		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Docket No.: PZ033P1C2

Ruben et al.

Application No.: Not Yet Assigned

Group Art Unit: N/A

Filed: Herewith

Examiner: Not Yet Assigned

For: 31 Human Secreted Proteins

STATEMENT UNDER 37 C.F.R. § 1.821(e)

MS SEQUENCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The above-identified patent application is a continuation of application Serial No. 09/531,119, filed March 20, 2000. The sequence listing of the instant application is identical to the sequence content of the computer readable sequence listing filed in connection with application Serial No. 09/531,119, on March 20, 2000.

In accordance with 37 C.F.R. § 1.821(e), please use the computer readable form filed in connection with application Serial No. 09/531,119 as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in the specification of the instant application filed herewith. Applicants hereby certify that the paper copy of the

Application No.: Not Yet Assigned

Docket No.: PZ033P1C2

Sequence Listing filed herewith and the computer readable sequence listing filed on March 20, 2000 in connection with application Serial No. 09/531,119 are the same and do not include new matter.

Respectfully submitted,

Dated: June 27, 2003

Mark J. Hyman

Registration No.: 46,789

HUMAN GENOME SCIENCES, INC.

9410 Key West Avenue

Rockville, Maryland 20850

(240) 314-1224